Table.
Change in clinical disease after G85R knockdown
| Transgenic | Onset | Early phase |
Late phase |
Disease duration |
Survival |
|---|---|---|---|---|---|
| G85Rflox/Cre-ER™ | 14.8% | 77.1% | 57.6% | 68.6% | 19.6% |
| G85Rflox/Lhx3:Cre | 14.6% | 87.5% | NS | 46.6% | 16.9% |
| G85Rflox/CD11b:Cre | NS | 58.8% | 37.5% | 43.2% | 12.5% |
Note: The numbers represent the per cent increase in the time to disease onset and increase in the duration of the early phase of disease, the late phase of disease, disease duration and survival compared to G85Rflox mice. The G85Rflox/Cre-ER™ mice were tamoxifen-treated. Data related to the knockdown in G85Rflox/Lhx:Cre mice (in which Cre is expressed in spinal and hindbrain MNs and a population of interneurons in the spinal cord) and G85Rflox/CD11b:Cre mice (in which Cre is expressed in microglia and activated macrophages) have been previously published (Wang et al. 2009b). NS=not statistically significant.